

Date: 24.05.2023

To, Department of Corporate Services, <b>BSE LIMITED</b> P. J. Towers, Dalal Street, Mumbai, Maharashtra-400001.  <b>ISIN : INE730E01016</b> <b>Scrip Code: 512217</b>	To, Listing Department, <b>Metropolitan Stock Exchange of India Limited (MSEI).</b> Vibgyor Towers, 4 <sup>th</sup> Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. <b>SYMBOL: PRISMMEDI</b>
---	--

**Subject: Submission of Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Reference: Prism Medico and Pharmacy Limited (BSE Code: 512217).**

**Dear Sir or Madam,**

With reference to captioned subject, please find enclosed herewith Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of shares acquired through Share Purchase Agreement.

Thanks & Regards,

**For Symbiosis Pharmaceuticals Private Limited  
(Promoter)**

**Name: Vishwambhar Dayal Gupta  
Designation: Director.**

**Cc: Prism Medico and Pharmacy Limited  
Suketi Road, Kala Amb, Sirmaur,  
Himachal Pradesh, 173030**

**Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers)  
Regulations, 2011**

Name of the Target Company (TC)	Prism Medico and Pharmacy Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Symbiosis Pharmaceuticals Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and Metropolitan Stock Exchange of India Limited		
<b>Details of the acquisition / disposal as follows</b>	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable(*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC (**)</b>
<b>Before the acquisition under consideration, holding of :</b>			
a) Shares carrying voting rights	50,000	0.83%	0.83%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
<b>e) Total (a+b+c+d)</b>	<b>50,000</b>	<b>0.83%</b>	<b>0.83%</b>
<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights acquired/(sold)	7,98,083	13.16%	13.16%
b) VRs acquired/sold otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/(sold) / (converted)	-	-	-
d) Shares encumbered/invoked/released by acquirer	-	-	-
<b>e) Total (a+b+c+d)</b>	<b>7,98,083</b>	<b>13.16%</b>	<b>13.16%</b>

<b>After the acquisition /sale, holding of:</b>			
a) Shares carrying voting rights	8,48,083	13.99%	13.99%
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
<b>e) Total (a+b+c+d)</b>	<b>8,48,083</b>	<b>13.99%</b>	<b>13.99%</b>
Mode of acquisition/sale (e.g. opens market / off market/ public issue / rights issue /preferential allotment / inter-se transfer, etc.)	Shares acquired through Share Purchase Agreement (“SPA”) dated 28.11.2022		
Date of acquisition /sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	22.05.2023		
Equity share capital / total voting capital of the TC before the said acquisition	60,63,428 Equity Shares of Face Value of Rs. 10/- Each		
Equity share capital/ total voting capital of the TC after the said acquisition	60,63,428 Equity Shares of Face Value of Rs. 10/- Each		
Total diluted share/voting capital of the TC after the said acquisition	60,63,428 Equity Shares of Face Value of Rs. 10/- Each		

**For Symbiosis Pharmaceuticals Private Limited  
(Promoter)**

**Name: Vishwambhar Dayal Gupta  
Designation: Director.**

**Place: Haryana  
Date: 24.05.2023**